German Federal Government invests 300 Million Euros in CureVac

German Federal Government invests 300 Million Euros in CureVac June 16, 2020, 11:03

This is a joint press release of the Federal Ministry of Economics and Energy and dievini Hopp Biotech holding.
A list of questions and answers regarding the investment of the German Federal Government can be found at the bottom of this page.

Main shareholder dievini Hopp BioTech and the Federal Government agree on a landmark investment in a company in the innovative biotechnology sector for the first time
Direct equity financing by the Federal Government is to be made by the Kreditanstalt für Wiederaufbau (KfW)
mRNA company CureVac retains complete operational and strategic independence; the Federal Government will not influence corporate policy decisions
It is a central step towards implementing the Corona Economic Stimulus and Future Technologies Package of the Federal Government from 03 June 2020

The German Federal Minister for Economic Affairs and Energy, Peter Altmaier, and Dietmar Hopp, SAP co-founder and co-founder of the investment company dievini Hopp BioTech holding GmbH & Co. KG, announced today that the Federal Republic of Germany will invest 300 million Euros in the biopharmaceutical company CureVac AG, a pioneer in the preclinical and clinical development of mRNA-based drugs.

Details of the investment, which will be made by the Kreditanstalt für Wiederaufbau (KfW), have been laid out in a definitive draft agreement. The funds from the capital increase will be used by CureVac for the further development of the Company’s proprietary pipeline and mRNA platform technology and the expansion of business activities. Under the agreement, the KfW will hold a stake of around 23 percent in CureVac.

curevac.com

investment COVID-19

or on to add a comment to scientific problem you are interested in!

Comments (0)

You may also be interested in

Amgen Profit Beats Estimates as Drugmaker Raises Forecast

Amgen Inc., the maker of cancer treatments and blood boosters to combat anemia, reported first-quarter profit that topped analysts’ estimates and raised its forecast for the year on stronger-than-expected drug sales. The shares rose in late trading.

Robots for stroke rehabilitation

Researchers at the University of Hertfordshire and a team of European partners have developed a prototype of a robotic glove which stroke sufferers can use in their own home to support rehabilitation and personal independence in receiving therapies.